Substrate Metabolism and Insulin Sensitivity in Patients With Hyperprolactinemia Before and After Treatment
Withdrawn
- Conditions
- Insulin ResistanceHyperprolactinemia
- Registration Number
- NCT00699530
- Lead Sponsor
- University of Aarhus
- Brief Summary
The purpose of this study is to investigate the effects of chronic elevated levels of Prolactin on metabolism and insulin sensitivity by studying patients with hyperprolactinemia before and after treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Written consent
- Age between 18 and 70
- At diagnose a serum prolactin > 200 microgram/l (10 U/l)
Exclusion Criteria
- Hypothyroidism
- Use of any medication
- Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin sensitivity Before and after treatment
- Secondary Outcome Measures
Name Time Method QoL, body composition, intrahepatic and intramyocellular fat, substrate metabolism, glucose tolerance Before and after treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link hyperprolactinemia to insulin resistance in NCT00699530?
How does Cabergoline compare to Bromocriptine in treating hyperprolactinemia-induced insulin resistance?
What biomarkers correlate with Cabergoline response in hyperprolactinemia patients with metabolic syndrome?
What are the long-term adverse effects of Cabergoline on glucose metabolism in hyperprolactinemia patients?
How do dopamine receptor agonists like Cabergoline modulate prolactin signaling pathways in metabolic disorders?
Trial Locations
- Locations (1)
Department of Endocrinology
🇩🇰Aarhus C, Aarhus, Denmark
Department of Endocrinology🇩🇰Aarhus C, Aarhus, Denmark